Jazz Pharmaceuticals Announces First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Jazz Pharma (JAZZ) EPS Miss Overshadowed By Settlements - UBS
May 11, 2016 9:05 AM EDTUBS analyst, Marc Goodman, raised his PT on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $168 from $162 as high single digit revenue growth was basically in line with expectations but EPS of $2.26 fell short of consensus $2.30. The Street was a little low on spending but the analyst thinks investors will quickly look through the slight EPS miss because of the newly disclosed Xyrem patent settlements out to 2025, which is better than expected. The firm... More
Mizuho Securities Upgrades Jazz Pharmaceuticals (JAZZ) to Buy on Xyrem Settlements
May 11, 2016 6:17 AM EDTMizuho Securities upgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Buy with a price target of $193.00 (from $137.00) on Xyrem Settlements.
Analyst Irina Koffler commented, "Jazz's announcement of its late 2025 Xyrem settlements was the upgrade signal we were looking for. We modeled Xyrem... More
Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 5c; Guides In-Line
May 10, 2016 4:08 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.26, $0.05 worse than the analyst estimate of $2.31. Revenue for the quarter came in at $336 million versus the consensus estimate of $338.86 million.
"During the first quarter of 2016, we executed on our business model by delivering strong top-... More
